



Issued: 10 March 2026, London UK

GSK tops Antimicrobial Resistance (AMR) Benchmark Report

GSK welcomes independent recognition of our leadership in addressing the urgent global threat of antimicrobial resistance (AMR) in the [AMR Benchmark Report](#), issued today. GSK's leading position among large biopharma companies reflects our continuous focus on delivering innovative antibiotic medicines and vaccines for patients where there is significant unmet medical need.

Tony Wood, Chief Scientific Officer, GSK, said: "Antimicrobial resistance is one of the most pressing scientific and medical challenges of our time, and we urgently need new medicines and vaccines for resistant infections. GSK is using cutting-edge technology to bring much-needed innovation to patients, including a new first-in-class antibiotic last year. While this is welcome progress, it is not enough and today's report underlines the need for governments and industry to work together to improve economic incentivisation of R&D and implement better access and stewardship models."

More than one million people die each year as a direct result of drug-resistant infections.¹

GSK has the strongest R&D pipeline of AMR-relevant medicines and vaccines in development (30) of any company assessed, and the most R&D projects targeting high-priority drug-resistant pathogens in need of new treatments.

In the last year alone, GSK secured approval of the first new oral antibiotic class for uncomplicated urinary tract infections in nearly 30 years, filed for regulatory approval for another new treatment, and announced six major new research programmes with the Fleming Initiative to find new ways to slow the progress of AMR using AI.

GSK is also recognised for supporting access to antimicrobials and vaccines in low- and middle-income countries, active participation in AMR surveillance programmes, and a comprehensive approach to responsible manufacturing.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries

Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Simon Moore	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
	Alison Hunt	+1 540 742 3391	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)

Media Statement

For media and investors only



Sam Piper	+44 (0) 7824 525779	(London)
Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

References

1 Murray, C.J.L., et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*, 2022.
